Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions

A condition, the technology of the subject, applied in the direction of DNA / RNA fragments, recombinant DNA technology, medical preparations containing active ingredients, etc., can solve the problem of not teaching the target sequence, etc.

Inactive Publication Date: 2009-06-03
ARROWHEAD RES CORP
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the publication does not teach specific target sequences for RNA inhibition as provided herein

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions
  • RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions
  • RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0151] Example 1 is used to specifically silence the interfering RNA of TNFR1 in GTM-3 cells

[0152] This study examined the ability of TNFR1 interfering RNA to knock down endogenous TNFR1 protein expression levels in cultured GTM-3 cells.

[0153] Use TNFR1 siRNAs, siCONTROL RISC-free-siRNA #1, or siCONTROL Non-Targeting siRNA #2 (NTC2) and Standard in vitro concentrations (0.1-10 nM) of #1 transfection reagent (Dharmacon, Lafayette, CO) accomplished transfection of GTM-3 cells (Pang, I.H. et al., 1994. Curr. Eye Res. 13:51-63). Dissolve all siRNA in 1X siRNA buffer, which is 20mM KCl, 6mM HEPES (pH7.5), 0.2mM MgCl 2 of aqueous solution. Control samples included a buffer control in which the volume of siRNA was replaced with an equal volume of IX siRNA buffer (-siRNA). Western blotting was performed using an anti-TNFR antibody (Santa Cruz Biotechnology, Santa Cruz, CA) to assess TNFRl protein expression. TNFR1 siRNA is a double-stranded interfering RNA specific for the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a RNA interferencefor inhibition of tumor necrosis factor a (TNFa) by silencing TNFa cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFa converting enzyme (TACE / ADAM17) mRNA expression. Silencing such TNFa targets, in particular, is useful for treating patients having a TNFa-related condition or at risk of developing a TNFa-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

Description

[0001] related application [0002] This application claims priority to co-pending U.S. Provisional Patent Application Serial No. 60 / 801,788, entitled "RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Associated Conditions," filed May 19, 2006, the contents of which are expressly incorporated This article serves as a reference. field of invention [0003] The application relates to the field of interfering RNA compositions, which are used to silence tumor necrosis factor alpha (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA or TNFα converting enzyme (TACE / ADAM17) mRNA . Silencing such TNFα targets is useful in the treatment of patients suffering from or at risk of developing a TNFα-related condition. Background of the invention [0004] Inflammation is usually treated with standard anti-inflammatory regimens including steroids and / or non-steroidal anti-inflammatory drugs (NSAIDS). Historically, allergic conjunctivitis, ocular inflammation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/11A61K31/713C07H21/02C12N15/113
CPCA61K31/713C12N2310/14C12N15/1137C12N15/1138A61K31/7088A61P7/10A61P11/02A61P11/06A61P17/04A61P27/02A61P27/04A61P27/06A61P27/14A61P29/00A61P43/00A61K48/00C07H21/02C07H21/04C12N2310/346C12N2310/351C12N2320/30
Inventor J·M·亚恩J·E·查特尔顿D·M·森基纳D·A·盖玛彻S·T·米勒
Owner ARROWHEAD RES CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com